Virtual, CEST Time
Past Meetings
654 meetings available
ESMO Academy Virtual Meeting 2021
Virtual, CEST Time
ESMO-EANM Virtual Advanced Course on Diagnostic and Therapeutic Applications of Nuclear Medicine in Oncology 2021
KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC
Switzerland
Virtual: ESO-ESMO Baltic and Eurasia Masterclass in Clinical Oncology
- CME:
- 25 Cat.1 ESMO-MORA points
- Languages:
- English
Virtual Meeting
ESMO World Congress on Gastrointestinal Cancer 2021
ECHNO-ICHNO 2021 Congress
Virtual, CEST Time
ESMO Gynaecological Cancers Virtual Congress 2021
Virtual, GMT +8
ESMO Virtual Advanced Course on EGFR-Mutated NSCLC 2021
Virtual, CEST Time
ESMO Virtual Preceptorship on Gastroenteropancreatic and Lung Neuroendocrine Neoplasms 2021
Virtual, Switzerland
Virtual: 16-ICML International Conference on Malignant Lymphoma
- CME:
- 20 Cat.1 ESMO-MORA points
- Languages:
- English
IMpassion050: A phase 3 study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy in high-risk, HER2-positive early breast cancer
IMpower133: Gene expression analysis in long-term survivors with ES-SCLC treated with first-line carboplatin and etoposide ± atezolizumab
Virtual, CEST Time
ESMO Virtual Advanced Course on Liquid Biopsy for Cancer Management 2021
Virtual, Switzerland
Best of ESMO Breast Cancer – UAE 2021 Virtual Edition
- Languages:
- English
Virtual
ESMO Virtual Summit Russia 2021
ASCO Annual Meeting Joint Session with ESMO
Virtual, CEST Time
ESMO Virtual Preceptorship on Hereditary Cancer Genetics 2021
ESMO Guidelines: Real World Cases - Webinar Series: Metastatic Breast Cancer
Virtual Meeting
The General Data Protection Regulation and Its Impact on Clinical Research
Virtual, CEST Time
Athens, Greece
27th Hellenic Conference of Clinical Oncology - Joint Session with ESMO
- CME:
- 23 cat.1 ESMO MORA points
- Languages:
- English
- Greek
Randomised Phase III Trial Data on the Efficacy and Safety of Cemiplimab as Opposed to Chemotherapy in Patients with Progressive Advanced Cervical Cancer
Randomised Phase II Trial Data on the Combination of 2nd-line Osimertinib and Bevacizumab Versus Standard of Care Osimertinib in EGFR T790M-mutated Advanced NSCLC
Virtual, GMT +8